Table 3.
Single-marker frequencies and association analyses with risk of PD
| Genotype frequency, n (%)a |
Dominant model |
Trend model |
|||||
|---|---|---|---|---|---|---|---|
| 1/1 | 1/2 | 2/2 | OR (95% CI) | p Value (pcorr value)b | OR (95% CI) | p Value | |
| rs363371 | |||||||
| Cases | 464 (66) | 208 (29.6) | 31 (4.4) | 0.72 (0.58–0.90) | 0.004 (0.03) | 0.78 (0.65–0.94) | 0.0088 (0.07) |
| Controls | 396 (58.5) | 245 (36.2) | 36 (5.3) | ||||
| rs363324 | |||||||
| Cases | 364 (52.5) | 259 (37.4) | 70 (10.1) | 0.76 (0.61–0.95) | 0.01 (0.08) | 0.85 (0.72–0.92) | 0.04 (0.32) |
| Controls | 304 (45.4) | 291 (43.5) | 74 (11.1) | ||||
| rs363333 | |||||||
| Cases | 576 (81.9) | 121 (17.2) | 6 (0.9) | 0.97 (0.74–1.28) | 0.85 | 0.94 (0.73–1.21) | 0.62 |
| Controls | 551 (81.3) | 116 (17.1) | 11 (1.6) | ||||
| rs363399 | |||||||
| Cases | 435 (61.8) | 229 (32.6) | 39 (5.6) | 0.83 (0.66–1.03) | 0.086 | 0.91 (0.76–1.10) | 0.34 |
| Controls | 387 (57.2) | 260 (38.5) | 29 (4.3) | ||||
| rs363387 | |||||||
| Cases | 596 (85.8) | 96 (13.8) | 3 (0.4) | 1.01 (0.74–1.37) | 0.95 | 0.97 (0.73–1.28) | 0.81 |
| Controls | 577 (85.5) | 91 (13.5) | 7 (1) | ||||
| rs363343 | |||||||
| Cases | 481 (68.4) | 203 (28.9) | 19 (2.7) | 1.01 (0.80–1.27) | 0.94 | 0.97 (0.80–1.19) | 0.78 |
| Controls | 463 (68.6) | 187 (27.7) | 25 (3.7) | ||||
| rs4752045 | |||||||
| Cases | 210 (29.8) | 335 (47.6) | 159 (22.6) | 0.85 (0.67–1.07) | 0.17 | 0.92 (0.79–1.07) | 0.27 |
| Controls | 181 (26.7) | 339 (50) | 158 (23.3) | ||||
| rs363236 | |||||||
| Cases | 461 (66) | 217 (31) | 21 (3) | 1.05 (0.84–1.32) | 0.68 | 1.03 (0.85–1.25) | 0.76 |
| Controls | 451 (66.9) | 200 (29.7) | 23 (3.4) | ||||
The estimated ORs and relative 95% CIs were adjusted for sex, age at enrollment, and smoking.
Key: PD, Parkinson’s disease; OR, odds ratio; CI, confidence interval.
a
Allele 1 (major frequency/wild-type allele) and allele 2 (minor frequency/variant allele) base type for each marker is specified in Table 1.
b
p Value after Bonferroni correction for 8 single-nucleotide polymorphism tests (α = 0.006). Significant value is indicated in bold.